This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation smallmolecules. This protective barrier prevents more than 98 percent of small-molecule drugs and all macromolecular therapeutics 3 from accessing the brain.
However, due to its unique biology and structural complexity, PAR2 has proven notoriously difficult for the pharmaceutical industry to effectively target. DT-9046 is an orally delivered smallmolecule that has reached pre-IND studies – making Domain the first company to successfully advance a smallmolecule candidate targeting PAR2.
According to Citeline’s Pharmaprojects tracking, some 21,000 molecules are in the drug development pipeline right now – and they are all being developed because they have the potential to change and save lives. Accelerate your drug development and clinical trial goals and benefit from our 360° CDMO and CRO solutions and expertise.
Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. Traditional drug discovery data architecture is manual, messy, proprietary and inflexible.
As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted smallmolecules aimed at revolutionising cancer treatment. I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development.
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Because LLMs are trained on extensive, internet-scale datasets, they can learn to identify contexts linking words and language.
Mass spectrometry imaging (MSI) enables the direct detection and quantitation of active pharmaceutical ingredients (APIs) and metabolites within tissue sections, making it widely regarded as a promising technique in the field of pharmacology and toxicology. For instance, Cheng et al. References [1].
With over two decades of experience in biomedical research, he is leading efforts to translate breakthrough GPCR biology into differentiated therapeutic strategies that can overcome immune resistance and offer new hope to patients with limited treatment options. This strategy is exemplified by its flagship programme: DT-7012.
Magazine ENEWS SUBSCRIBE WEBINARS PODCASTS EBOOKS ABOUT US Edit submissions Media kit Innovation Awards Articles Flow state: The evolving shape of continuous manufacturing June 17, 2025 While the pharmaceutical industry has been slow to adopt continuous manufacturing, it appears to be gaining momentum.
Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise. The result of their research is what’s now described as targeted protein degradation, which conceptually is a bit like ordering a junk hauling service for the cell.
Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in smallmolecule drug discovery. Before a compound can become a viable therapy, it must pass a series of tests – not just for potency, but for how it behaves in the body.
Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.
1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 1] [2] It was developed by Vertex Pharmaceuticals , [5] and was approved for medical use in the United States in January 2025. [2] acting director of the FDA’s Center for Drug Evaluation and Research.
Yet, there is a promising future for agonist antibodies of immune checkpoint regulators as researchers continue to unveil their intricate mechanisms of action, offering novel avenues for advancing precision medicine in immunology and inflammatory disorders. References 1 Tinoco R, Otero DC, Takahashi AA, Bradley LM.
The Rise of Biosimilars: A Healthcare Revolution Biosimilars, often referred to as the “generic equivalents” of biologic drugs, have been making waves in the pharmaceutical industry for over a decade. This may include implementing gain-sharing models, where savings from biosimilar use are reinvested in patient care or research.
Medical researchers and practitioners see in their own patients how these ailments interconnect and overlap, as do the pharmaceutical and biotech companies working to develop GLP-1 therapeutics. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.
into a “ center of excellence ” that will produce a wide range of smallmolecules and biologic drugs, including protein-degrading “PROTACs” and antibody-drug conjugates. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
Like water flowing down a hill, protons descending down the electrochemical gradient turn the crank of this turbine, which provides the energy required to snap ADP and phosphate together to form the body’s main energy storage molecule, ATP. Pharmacological induction of metabolic stress might prove useful outside of obesity, too.
Smallmolecule drugs make up most of the drugs we take conveniently as pills, including painkillers like ibuprofen (Advil), antibiotics like penicillin and amoxicillin, or cholesterol-lowering drugs like atorvastatin (Lipitor). The smallmolecules drugs of today look nothing like the molecules of the 1970s.
49 Akilo-scale, chromatography-freesynthesisofhetrombopag has been reported by researchers at Jiangsu Hengrui Pharmaceutical in the Chinese-language patent literature (Scheme 12).50,51 Hetrombopag Olamine , RAFUTROMBOPAG OLAMINE Hetrombopag diolamine SHR8735 olamine Hetrombopag ethanolamine SHR-8735 olamine 580.6
Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel smallmolecule to target autoimmune disease.
Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.
These therapies have broadened treatment options for patients to expand beyond the more traditional smallmolecule drug alternatives. 2 However, when dosed at the MTD, ADCs display improved efficacy over smallmolecules in oncology trials. 3D rendering of Antibody Drug Conjugate Molecules.
By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new smallmolecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.
Miniature Swine: Changing the Bias for Nonclinical Studies on SmallMolecules and Biologics pmjackson Fri, 07/28/2023 - 16:07 Miniature swine have been widely used for research studies since the 1960s—most commonly within the scope of dermal testing due to similarities of their integument to humans. Click here to read more.
Miniature Swine: Changing the Bias for Nonclinical Studies on SmallMolecules and Biologics pmjackson Fri, 07/28/2023 - 16:07 Miniature swine have been widely used for research studies since the 1960s—most commonly within the scope of dermal testing due to similarities of their integument to humans. Click here to read more.
1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional smallmolecules. 1 The concept of TPD was first demonstrated with a heterobifunctional smallmolecule to degrader a protein of interest in the early 2000s.
Researchers would sift through natural extracts , hoping to stumble upon a compound that exhibited beneficial effects. In fact, it's one of the most exciting areas in drug research today. With billions in funding and innovative research, we're starting to see strategies that can tackle these tough targets.
Dian eventually made her way to Shanghai, where she encountered a much bigger world while earning degrees in pharmaceutical engineering and medicinal chemistry. researching DNA photoproducts related to skin cancer. Remember my post-doc research? She seized the opportunity to pursue a higher degree in the U.S., Proteomics!
Autophagy in a hot topic in scientific circles; the number of papers that mention the process has risen almost exponentially since Yoshinori Ohsumi was awarded the Nobel Prize in 2016 for his research into its underlying mechanisms. Autophagy boosters, in contrast, are conventional smallmolecule drugs. cited 2023 Sep 5].
Sygnature Discovery is pleased to have entered into a research collaboration agreement with the global healthcare group Daewoong Pharmaceutical to accelerate the discovery of a novel smallmolecule to target autoimmune disease.
In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Here, researchers are looking at allosteric modulation—hitting different parts of the molecule to increase selectivity.
Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. Acta Cryst. Acta Cryst. 2013) 56, 2059-2073.
The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral smallmolecules against predicted future variants of SARS-CoV-2 and other related human viruses. References. Hilgenfeld, Febs J. 2014), 281, 4085-4096.
As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel orally administered first-in-class smallmolecule that was developed based on an anti-virulence approach targeting Staphylococcus aureus including MRSA. About ALS-4. About Aptorum Group.
By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.
Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel smallmolecules that target ?-synuclein is a leading global research and development-based pharmaceutical company headquartered in Japan.
Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists.
NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.
Sosei Heptares will receive an upfront payment of US$10 million, plus downstream payments of up to US$370 million, plus tiered royalties.
Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016.
Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 , taking place over two weeks on April 10-15 and May 17-21, 2021. The product is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Between 2000 and 2020, approximately 30 percent of the newly introduced smallmolecule drugs were derived from natural products. In short, this hypothesis underscores the potential benefits of aligning pharmaceutical development more closely with nature.
However, in tissues where the 3 Hs are not present, the smallmolecule has anti-toxicity activity through 1) direct inhibition of the NLRP3 inflammasome, an inflammation starter and perpetuator, and 2) upregulation of the master antioxidant transcription factor, Nrf2. Journal of Cancer Research and Clinical Oncology.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content